# US 2020/0399383 A1 · Chimeric antigen receptor therapy in combination with il-15r and il15

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2020/0399383 A1
- Document ID: US20200399383A1
- Status: Published application
- Kind: A1
- Application number: 16/969,381
- Filed: 2019-02-13
- Published: 2020-12-24
- Earliest claimed: 2018-02-13
- Assignees: Novartis AG; The Trustees of the University of Pennsylvania
- Applicants: Novartis AG; The Trustees of the University of Pennsylvania
- Inventors: John Scholler; Carl H. June
- Web page: https://patentgrep.com/patent/US20200399383A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- C07K 16/2866: {against receptors for cytokines, lymphokines, interferons}
- A61K 40/11: T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
- A61K 40/31: Chimeric antigen receptors [CAR]
- A61K 40/35: Cytokines
- A61K 40/4211: {CD19 or B4}
- A61K 40/4255: {Mesothelin [MSLN]}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/5443: {IL-15}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/7155: {for interleukins [IL]}
- C07K 16/00: Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K 16/244: {Interleukins [IL]}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- C07K 16/2803: {against the immunoglobulin superfamily}
- C07K 16/2878: {against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95}
- C07K 16/30: from tumour cells
- C12N 15/86: Viral vectors
- A61K 2039/55527: {Interleukins}
- A61K 2039/852: {Pancreas}
- A61K 2239/31: characterized by the route of administration
- A61K 2239/38: characterised by the dose, timing or administration schedule
- A61K 2239/48: Blood cells, e.g. leukemia or lymphoma
- A61K 2239/54: Pancreas
- C07K 2317/622: Single chain antibody (scFv)
- C07K 2317/73: Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K 2319/03: containing a transmembrane segment
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)

## Abstract

The invention provides compositions and methods for treating diseases such as cancer. The invention also relates to a method of administering a therapy comprising a chimeric antigen receptor, an IL-15R molecule and an IL-15 molecule.

## Claims

### Claim 1

A nucleic acid molecule, e.g., an isolated nucleic acid molecule, comprising
(i) a first nucleic acid sequence encoding a chimeric antigen receptor (CAR) molecule that binds to an antigen (e.g., CD19, Mesothelin or BCMA);
(ii) a second nucleic acid sequence comprising an IL-15 receptor (IL-15R) molecule; and
(iii) a third nucleic acid sequence comprising an IL-15 molecule,
wherein the first nucleic acid sequence, second nucleic acid sequence and third nucleic acid sequence are disposed on a single nucleic acid molecule, e.g., a viral vector, e.g., a lentivirus vector.

### Claim 2 (depends on 1)

The nucleic acid molecule of claim 1, comprising a multicistronic lentivirus vector.

### Claim 3 (depends on 1, 2)

The nucleic acid molecule of claim 1 or 2, wherein the single nucleic acid molecule has the following arrangement in an N- to C-terminal orientation:
(i) the first nucleic acid sequence-a first linker-the second nucleic acid sequence-a second linker-the third nucleic acid sequence; or
(ii) the first nucleic acid sequence-a first linker-the third nucleic acid sequence-a second linker-the second nucleic acid sequence,
wherein the first and second linkers are different.

### Claim 4 (depends on 1, 2)

The nucleic acid molecule of claim 1 or 2, wherein the single nucleic acid molecule has the following arrangement in an N- to C-terminal orientation:
(iii) the second nucleic acid sequence-a first linker-the third nucleic acid sequence-a second linker-the first nucleic acid sequence; or
(iv) the third nucleic acid sequence-a first linker-the second nucleic acid sequence-a second linker-the first nucleic acid sequence,
wherein the first and second linkers are different.

### Claim 5 (depends on 3, 4)

The nucleic acid molecule of claim 3 or 4, wherein the linker encodes a self-cleavage site, e.g., a P2A site, a T2A site, an E2A site, or an F2A site.

### Claim 6 (depends on 3, 4, 5)

The nucleic acid molecule of any of claims 3-5, wherein the first linker encodes a P2A site and the second linker encodes a T2A site, wherein:
(i) the first linker comprises the nucleotide sequence of SEQ ID NO: 23 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions, deletions, or modifications), and/or
(ii) the second linker comprises a nucleotide sequence encoding SEQ ID NO: 1478 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions, deletions, or modifications).

### Claim 7

The nucleic acid molecule of any of the preceding claims, wherein the CAR molecule comprises, in an N- to C-terminal orientation, an antigen binding domain that binds to the antigen, a transmembrane domain, and an intracellular signaling domain, optionally wherein the antigen binding domain is connected to the transmembrane domain by a hinge domain.

### Claim 8 (depends on 7)

The nucleic acid molecule of claim 7, further comprising a leader sequence.

### Claim 9

The nucleic acid molecule of any of the preceding claims, wherein the third nucleic acid sequence encodes an amino acid comprising the sequence of SEQ ID NO: 1002, a sequence at least about 85%, 90%, 95%, 99% or more identical to SEQ ID NO:1002, or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications compared to SEQ ID NO: 1002.

### Claim 10

The nucleic acid molecule of any of the preceding claims, wherein the second nucleic acid sequence encodes an amino acid comprising the sequence of SEQ ID NO: 1001, a sequence at least about 85%, 90%, 95%, 99% or more identical to SEQ ID NO:1001, or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications compared to SEQ ID NO: 1001.

### Claim 11

The nucleic acid molecule of any of the preceding claims, wherein the antigen is selected from: CD19; CD123; CD22; CD30; CD171; CS-1; C-type lectin-like molecule-1, CD33; epidermal growth factor receptor variant III (EGFRvIII); ganglioside G2 (GD2); ganglioside GD3; TNF receptor family member; B-cell maturation antigen; Tn antigen ((Tn Ag) or (GalNAcα-Ser/Thr)); prostate-specific membrane antigen (PSMA); Receptor tyrosine kinase-like orphan receptor 1 (ROR1); Fms-Like Tyrosine Kinase 3 (FLT3); Tumor-associated glycoprotein 72 (TAG72); CD38; CD44v6; Carcinoembryonic antigen (CEA); Epithelial cell adhesion molecule (EPCAM); B7H3 (CD276); KIT (CD117); Interleukin-13 receptor subunit alpha-2; Mesothelin; Interleukin 11 receptor alpha (IL-11Ra); prostate stem cell antigen (PSCA); Protease Serine 21; vascular endothelial growth factor receptor 2 (VEGFR2); Lewis (Y) antigen; CD24; Platelet-derived growth factor receptor beta (PDGFR-beta); Stage-specific embryonic antigen-4 (SSEA-4); CD20; Folate receptor alpha; Receptor tyrosine-protein kinase ERBB2 (Her2/neu); Mucin 1, cell surface associated (MUC1); epidermal growth factor receptor (EGFR); neural cell adhesion molecule (NCAM); Prostase; prostatic acid phosphatase (PAP); elongation factor 2 mutated (ELF2M); Ephrin B2; fibroblast activation protein alpha (FAP); insulin-like growth factor 1 receptor (IGF-I receptor), carbonic anhydrase IX (CAIX); Proteasome (Prosome, Macropain) Subunit, Beta Type, 9 (LMP2); glycoprotein 100 (gp100); oncogene polypeptide consisting of breakpoint cluster region (BCR) and Abelson murine leukemia viral oncogene homolog 1 (Abl) (bcr-abl); tyrosinase; ephrin type-A receptor 2 (EphA2); Fucosyl GM1; sialyl Lewis adhesion molecule (sLe); ganglioside GM3; transglutaminase 5 (TGS5); high molecular weight-melanoma-associated antigen (HMWMAA); o-acetyl-GD2 ganglioside (OAcGD2); Folate receptor beta; tumor endothelial marker 1 (TEM1/CD248); tumor endothelial marker 7-related (TEM7R); claudin 6 (CLDN6); thyroid stimulating hormone receptor (TSHR); G protein-coupled receptor class C group 5, member D (GPRC5D); chromosome X open reading frame 61 (CXORF61); CD97; CD179a; anaplastic lymphoma kinase (ALK); Polysialic acid; placenta-specific 1 (PLAC1); hexasaccharide portion of globoH glycoceramide (GloboH); mammary gland differentiation antigen (NY-BR-1); uroplakin 2 (UPK2); Hepatitis A virus cellular receptor 1 (HAVCR1); adrenoceptor beta 3 (ADRB3); pannexin 3 (PANX3); G protein-coupled receptor 20 (GPR20); lymphocyte antigen 6 complex, locus K 9 (LY6K); Olfactory receptor 51E2 (OR51E2); TCR Gamma Alternate Reading Frame Protein (TARP); Wilms tumor protein (WT1); Cancer/testis antigen 1 (NY-ESO-1); Cancer/testis antigen 2 (LAGE-1a); Melanoma-associated antigen 1 (MAGE-A1); ETS translocation-variant gene 6, located on chromosome 12p (ETV6-AML); sperm protein 17 (SPA17); X Antigen Family, Member 1A (XAGE1); angiopoietin-binding cell surface receptor 2 (Tie 2); melanoma cancer testis antigen-1 (MAD-CT-1); melanoma cancer testis antigen-2 (MAD-CT-2); Fos-related antigen 1; tumor protein p53 (p53); p53 mutant; prostein; surviving; telomerase; prostate carcinoma tumor antigen-1, melanoma antigen recognized by T cells 1; Rat sarcoma (Ras) mutant; human Telomerase reverse transcriptase (hTERT); sarcoma translocation breakpoints; melanoma inhibitor of apoptosis (ML-IAP); ERG (transmembrane protease, serine 2 (TMPRSS2) ETS fusion gene); N-Acetyl glucosaminyl-transferase V (NA17); paired box protein Pax-3 (PAX3); Androgen receptor; Cyclin B1; v-myc avian myelocytomatosis viral oncogene neuroblastoma derived homolog (MYCN); Ras Homolog Family Member C (RhoC); Tyrosinase-related protein 2 (TRP-2); Cytochrome P450 1B1 (CYP1B1); CCCTC-Binding Factor (Zinc Finger Protein)-Like, Squamous Cell Carcinoma Antigen Recognized By T Cells 3 (SART3); Paired box protein Pax-5 (PAX5); proacrosin binding protein sp32 (OY-TES1); lymphocyte-specific protein tyrosine kinase (LCK); A kinase anchor protein 4 (AKAP-4); synovial sarcoma, X breakpoint 2 (SSX2); Receptor for Advanced Glycation Endproducts (RAGE-1); renal ubiquitous 1 (RU1); renal ubiquitous 2 (RU2); legumain; human papilloma virus E6 (HPV E6); human papilloma virus E7 (HPV E7); intestinal carboxyl esterase; heat shock protein 70-2 mutated (mut hsp70-2); CD79a; CD79b; CD72; Leukocyte-associated immunoglobulin-like receptor 1 (LAIR1); Fc fragment of IgA receptor (FCAR or CD89); Leukocyte immunoglobulin-like receptor subfamily A member 2 (LILRA2); CD300 molecule-like family member f (CD300LF); C-type lectin domain family 12 member A (CLEC12A); bone marrow stromal cell antigen 2 (BST2); EGF-like module-containing mucin-like hormone receptor-like 2 (EMR2); lymphocyte antigen 75 (LY75); Glypican-3 (GPC3); Fc receptor-like 5 (FCRL5); or immunoglobulin lambda-like polypeptide 1 (IGLL1).

### Claim 12

The nucleic acid molecule of any of the preceding claims, wherein the antigen is chosen from CD19, CD22, BCMA, CD20, CD123, EGFRvIII, or mesothelin.

### Claim 13

The nucleic acid molecule of any of the preceding claims, wherein the antigen is a solid tumor antigen.

### Claim 14

The nucleic acid molecule of any of the preceding claims, wherein the antigen is selected from mesothelin, EGFRvIII, GD2, Tn antigen, sTn antigen, Tn-O-Glycopeptides, sTn-O-Glycopeptides, PSMA, CD97, TAG72, CD44v6, CEA, EPCAM, KIT, IL-13Ra2, leguman, GD3, CD171, IL-11Ra, PSCA, MAD-CT-1, MAD-CT-2, VEGFR2, LewisY, CD24, PDGFR-beta, SSEA-4, folate receptor alpha, ERBBs (e.g., ERBB2), Her2/neu, MUC1, EGFR, NCAM, Ephrin B2, CAIX, LMP2, sLe, HMWMAA, o-acetyl-GD2, folate receptor beta, TEM1/CD248, TEM7R, FAP, Legumain, HPV E6 or E7, ML-IAP, CLDN6, TSHR, GPRC5D, ALK, polysialic acid, Fos-related antigen, neutrophil elastase, TRP-2, CYP1B1, sperm protein 17, beta human chorionic gonadotropin, AFP, thyroglobulin, PLAC1, globoH, RAGE1, MN-CA IX, human telomerase reverse transcriptase, intestinal carboxyl esterase, mut hsp 70-2, NA-17, NY-BR-1, UPK2, HAVCR1, ADRB3, PANX3, NY-ESO-1, GPR20, Ly6k, OR51E2, TARP, or GFRα4.

### Claim 15

The nucleic acid molecule of any of the preceding claims, wherein the transmembrane domain comprises a transmembrane domain of a protein chosen from the alpha, beta or zeta chain of the T-cell receptor, CD28, CD3 epsilon, CD45, CD4, CD5, CD8, CD9, CD16, CD22, CD33, CD37, CD64, CD80, CD86, CD123, CD134, CD137 or CD154,
optionally wherein the transmembrane domain comprises:
(i) a transmembrane domain of CD8; or
(ii) the amino acid sequence of SEQ ID NO: 1026 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions or deletions, e.g., conserved substitutions).

### Claim 16

The nucleic acid molecule of any of the preceding claims, wherein the intracellular signaling domain comprises a primary signaling domain, optionally wherein the primary signaling domain comprises:
(i) a functional signaling domain derived from CD3 zeta, TCR zeta, FcR gamma, FcR beta, CD3 gamma, CD3 delta, CD3 epsilon, CD5, CD22, CD79a, CD79b, CD278 (ICOS), FcεRI, DAP10, DAP12, or CD66d; or
(ii) the amino acid sequence of SEQ ID NO: 1034 or 1037 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions or deletions, e.g., conserved substitutions).

### Claim 17

The nucleic acid molecule of any of the preceding claims, wherein the intracellular signaling domain comprises a costimulatory domain, optionally wherein:
(i) the costimulatory domain comprises a functional signaling domain derived from MHC class I molecule, TNF receptor protein, Immunoglobulin-like protein, cytokine receptor, integrin, signalling lymphocytic activation molecule (SLAM), activating NK cell receptor, BTLA, a Toll ligand receptor, OX40, CD2, CD7, CD27, CD28, CD30, CD40, CD5, ICAM-1, 4-1BB (CD137), B7-H3, ICOS (CD278), GITR, BAFFR, LIGHT, HVEM (LIGHTR), KIRDS2, SLAMF7, NKp80 (KLRF1), NKp44, NKp30, NKp46, CD19, CD4, CD8alpha, CD8beta, IL2R beta, IL2R gamma, IL7R alpha, ITGA4, VLA1, CD49a, ITGA4, IA4, CD49D, ITGA6, VLA-6, CD49f, ITGAD, CD11d, ITGAE, CD103, ITGAL, CD11a, LFA-1, ITGAM, CD11b, ITGAX, CD11c, ITGB1, CD29, ITGB2, CD18, ITGB7, NKG2D, NKG2C, TNFR2, TRANCE/RANKL, DNAM1 (CD226), SLAMF4 (CD244, 2B4), CD84, CD96 (Tactile), CEACAM1, CRTAM, Ly9 (CD229), CD160 (BY55), PSGL1, CD100 (SEMA4D), CD69, SLAMF6 (NTB-A, Ly108), SLAM (SLAMF1, CD150, IPO-3), BLAME (SLAMF8), SELPLG (CD162), LTBR, LAT, GADS, SLP-76, PAG/Cbp, CD19a, CD28-OX40, CD28-4-1BB, or a ligand that specifically binds with CD83;
(ii) the costimulatory domain comprises a functional signaling domain derived from 4-1BB; or
(iii) the costimulatory domain comprises the amino acid sequence of SEQ ID NO: 1029 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions or deletions, e.g., conserved substitutions).

### Claim 18

A CAR IL-15/IL15R polypeptide comprising:
(i) a chimeric antigen receptor (CAR) molecule that binds to an antigen (e.g., an antigen described herein, e.g., CD19 or Mesothelin);
(ii) an IL-15 receptor (IL-15R) molecule; and
(iii) an IL-15 molecule,
wherein (i)-(iii) are expressed in the same frame on a single polypeptide chain.

### Claim 19 (depends on 18)

The polypeptide of claim 18, wherein the polypeptide has the following arrangement in an N- to C-terminal orientation:
CAR molecule-a first linker-IL-15R molecule-a second linker-IL-15 molecule
wherein the first and second linkers are different.

### Claim 20 (depends on 18)

The polypeptide of claim 18, wherein the polypeptide has the following arrangement in an N- to C-terminal orientation:
CAR molecule-a first linker-IL-15 molecule-a second linker-IL-15R molecule,
wherein the first and second linkers are different.

### Claim 21 (depends on 18)

The polypeptide of claim 18, wherein the polypeptide has the following arrangement in an N- to C-terminal orientation:
IL-15R molecule-a first linker-IL-15 molecule-a second linker-CAR molecule; or
IL-15 molecule-a first linker-IL-15R molecule-a second linker-CAR molecule,
wherein the first and second linkers are different.

### Claim 22 (depends on 18, 19, 20, 21)

The polypeptide of any of claims 18-21, wherein the wherein the first linker comprises a P2A site and the second linker comprises a T2A site, wherein:
(i) the first linker comprises the amino acid sequence of SEQ ID NO: 1479 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions, deletions, or modifications), and/or
(ii) the second linker comprises the amino acid sequence of SEQ ID NO: 1478 (or a sequence at least about 85%, 90%, 95%, 99% or more identical thereto, and/or having one, two, three or more substitutions, insertions, deletions, or modifications).

### Claim 23 (depends on 18, 19, 20, 21, 22)

The polypeptide of any of claims 18-22, wherein the CAR molecule comprises, in an N- to C-terminal orientation, an antigen binding domain that binds to the antigen, a transmembrane domain, and an intracellular signaling domain, optionally wherein the antigen binding domain is connected to the transmembrane domain by a hinge domain.

### Claim 24 (depends on 18, 19, 20, 21, 22, 23)

The polypeptide of any of claims 18-23, comprising the amino acid sequence of SEQ ID NO: 1002, a sequence at least about 85%, 90%, 95%, 99% or more identical to SEQ ID NO: 1002, or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications compared to SEQ ID NO: 1002.

### Claim 25 (depends on 18, 19, 20, 21, 22, 23, 24)

The polypeptide of any of claims 18-24, comprising the amino acid sequence of SEQ ID NO: 1001, a sequence at least about 85%, 90%, 95%, 99% or more identical to SEQ ID NO:1001, or a sequence having one, two, three or more substitutions, insertions, deletions, or modifications compared to SEQ ID NO: 1001.

### Claim 26 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A cell, e.g., an immune effector cell, comprising the nucleic acid molecule of any of claims 1-17 or the polypeptide of any of claims 18-25.

### Claim 27 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25)

A vector, e.g., lentiviral vector, comprising the nucleic acid molecule of any of claims 1-17, or a nucleic acid encoding the polypeptide of any of claims 18-25.

### Claim 28 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 27)

A method of making a population of immune effector cells expressing Chimeric Antigen Receptor (CAR) molecule, IL-15R molecule and IL-15 molecule (“CAR IL-15/IL-15R expressing cells”), comprising:
a) providing a population of immune effector cells, e.g., T cells or NK cells;
b) contacting the population of immune effector cells with a nucleic acid molecule of any of claims 1-15, or a vector of claim 27; and
c) maintaining the cells under conditions that allow expression of the CAR polypeptide, thereby making a population of CAR IL-15/IL-15R expressing immune effector cells.

### Claim 29 (depends on 28)

The method of claim 28, wherein the nucleic acid is DNA or RNA.

### Claim 30 (depends on 28, 29)

The method of any of claim 28 or 29, wherein (b) comprises performing lentiviral transduction to deliver the nucleic acid to the immune effector cells.

### Claim 31 (depends on 28, 29, 30)

The method of claim any of claims 28-30, further comprising contacting the population of cells with a ligand, e.g., with an extracellular ligand, that binds to the CAR molecule, thereby stimulating the population of cells.

### Claim 32 (depends on 31)

The method of claim 31, wherein the ligand comprises a cognate antigen molecule or an antibody molecule that binds to the CAR molecule.

### Claim 33 (depends on 32)

The method of claim 32, wherein the ligand, e.g., cognate antigen molecule, is immobilized, e.g., on a substrate, e.g., a bead or a cell, or is soluble.

### Claim 34 (depends on 31, 32, 33)

The method of any of claims 31-33, wherein the population of cells is contacted, e.g., stimulated, with the cognate antigen molecule at least 1 time, 2 times, 3 times, 4 times, 5 times, 6 times, 7 times or 8 times, e.g., 4 times, wherein each contact period, e.g., stimulation, lasts for about 1 week.

### Claim 35 (depends on 31, 32, 33, 34)

The method of any of claims 31-34, further comprising contacting the population of cells with an IL-21 molecule.

### Claim 36 (depends on 35)

The method of claim 35, wherein the IL-21 molecule is provided at an amount of at least 5, 10, 15, 20, 30, 40, 50 or 100 ug/ml, e.g., 10 ug/ml.

### Claim 37 (depends on 35, 36)

The method of claim 35 or 36, wherein the IL-21 molecule promotes a naïve T cell phenotype, e.g., CD45RO− CCR7+.

### Claim 38 (depends on 31, 32, 33, 34)

The method of any of claims 31-34, wherein following contacting, e.g., stimulating, with the cognate antigen molecule, the population of cells is not contacted with an exogenous cytokine or cognate antigen molecule.

### Claim 39 (depends on 31, 32, 33, 34, 35, 36, 37, 38)

The method of any of claims 31-38, wherein the population of cells is maintained for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15 or 20 weeks, e.g., 10 weeks.

### Claim 40 (depends on 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 31-39, wherein the population of cells has one, two, three, four or all of the following characteristics:
(i) no or minimal loss in viability as measured by an assay of Example 1;
(ii) ability to have an antigen specific response, as measured by an assay of Example 1;
(iii) ability to induce degranulation, e.g., as measured by CD107a expression, as measured by an assay of Example 1;
(iv) ability to induce IFN-g release, e.g., as measured by IFN-g expression in an assay of Example 1; or
(v) mitochondrial activity as measured by an assay of Example 1,
compared to an otherwise similar CAR IL-15/IL-15R expressing population prior to culturing without cytokine or antigen, e.g., at four weeks after contacting, e.g., stimulation, with a cognate antigen molecule.

### Claim 41 (depends on 28, 31)

The method of claim 28 or 31, which results in an increase in the population of cells expressing CD45RO−CCR7+, e.g., by about at least 10%, 20%, 30%, 40%, 50%, 60%, 70%, 80%, 90%, 95%, 100% or greater, compared to a population of immune effector cells contacted with a nucleic acid molecule encoding a CAR molecule without IL-15R and/or IL-15.

### Claim 42 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39)

The method of any of claims 28-39, comprising:
(i) expanding the population of cells, e.g., for at least 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, or 28 days or for 1-7, 7-14, 14-21, or 14-28 days; or
(ii) expanding the population of cells, e.g., by at least, 5, 10, 20, 30, 40, 50, 60, 70, 80, 90, or 100-fold change in cell number or more, e.g., up to about 40 or 50-fold, e.g., under growth conditions of Example 1.

### Claim 43 (depends on 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42)

The method of any of claims 28-42, wherein the population of CAR IL-15/IL-15R expressing cell exhibits enhanced anti-tumor efficacy compared to a population of cells expressing a CAR molecule, as measured by an assay of Example 1.

### Claim 44

A method of evaluating a population of CAR IL-15/IL-15R expressing cells, comprising measuring the level, e.g., activity or expression level, of CD45RO and CCR7 in the population of cells, wherein:
a low level of CD45RO expression (e.g., CD45RO−) and a high level of CCR7 expression (e.g., CCR7+) is indicative that the sample is suitable for treatment; and
a high level of CD45RO expression (e.g., CD45RO+) and a low level of CCR7 expression (e.g., CCR7−) is indicative that the sample is not suitable for treatment
thereby evaluating the CAR-IL-15 complex expressing cell.

### Claim 45

A cell, e.g., an immune effector cell, e.g., a T cell or NK cell, comprising:
(i) a first nucleic acid sequence encoding a chimeric antigen receptor (CAR) molecule that binds to an antigen (e.g., an antigen described herein);
(ii) a second nucleic acid sequence encoding an IL-15 receptor (IL-15R) molecule; and
(iii) a third nucleic acid sequence encoding an IL-15 molecule,
wherein the first nucleic acid sequence, the second nucleic acid sequence, and the third nucleic acid sequence are disposed on a single nucleic acid molecule.

### Claim 46 (depends on 45)

The cell of claim 45, wherein the single nucleic acid molecule has the following arrangement in an N- to C-terminal orientation:
(i) the first nucleic acid sequence-a first linker-the second nucleic acid sequence-a second linker-the third nucleic acid sequence; or
(ii) the first nucleic acid sequence-a first linker-the third nucleic acid sequence-a second linker-the second nucleic acid sequence,
wherein the first and second linkers are different.

### Claim 47 (depends on 45, 46)

The cell of claim 45 or 46, wherein the single nucleic acid molecule has the following arrangement in an N- to C-terminal orientation:
(iii) the second nucleic acid sequence-a first linker-the third nucleic acid sequence-a second linker-the first nucleic acid sequence; or
(iv) the third nucleic acid sequence-a first linker-the second nucleic acid sequence-a second linker-the first nucleic acid sequence,
wherein the first and second linkers are different.

### Claim 48 (depends on 46, 47)

The cell of claim 46 or 47, wherein the linker encodes a self-cleavage site, e.g., a P2A site, a T2A site, an E2A site, or an F2A site.

### Claim 49 (depends on 45, 46, 47, 48)

The cell of any one of claims 45-48, wherein the CAR molecule comprises, in an N- to C-terminal orientation, an antigen binding domain that binds to the antigen, a transmembrane domain, and an intracellular signaling domain, optionally wherein the antigen binding domain is connected to the transmembrane domain by a hinge domain.

### Claim 50 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 45, 46, 47, 48, 49)

A method of treating a subject having a disease associated with expression of an antigen, e.g., a tumor antigen described herein, e.g., CD19, Mesothelin or BCMA, comprising administering to the subject an effective number of a population of cells of any one of claims 45-49, or a population of cells comprising the nucleic acid molecule of any of claims 1-17, or a population of cells comprising the polypeptide of any of claims 18-25.

### Claim 51 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 45, 46, 47, 48, 49, 50, 51)

A method of providing an anti-cancer immune response in a subject having a disease associated with expression of an antigen, e.g., a tumor antigen described herein, e.g., CD19, Mesothelin or BCMA, comprising administering to the subject an effective number of a population of cells of any one of claims 45-51, or a population of cells comprising the nucleic acid molecule of any of claims 1-17, or a population of cells comprising the polypeptide of any of claims 18-25, thereby providing the anti-cancer immune response.

### Claim 52 (depends on 50, 51)

The method of claim 50 or 51, wherein the disease associated with expression of an antigen, e.g., a tumor antigen described herein, e.g., CD19, Mesothelin or BCMA, is a cancer.

### Claim 53 (depends on 52)

The method of claim 52, wherein the cancer is a solid tumor.

### Claim 54 (depends on 52, 53)

The method of claim 52 or 53, wherein the cancer is chosen from mesothelioma (e.g., malignant pleural mesothelioma); lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, squamous cell lung cancer, or large cell lung cancer); pancreatic cancer (e.g., pancreatic ductal adenocarcinoma, or metastatic pancreatic ductal adenocarcinoma (PDA)); esophageal cancer (e.g., esophageal adenocarcinoma), ovarian cancer (e.g., serous epithelial ovarian cancer), breast cancer, colorectal cancer, bladder cancer, glioblastoma, prostate cancer, cervical cancer, skin cancer, melanoma, renal cancer, liver cancer, brain cancer, thymoma, sarcoma, carcinoma, uterine cancer, kidney cancer, gastrointestinal cancer, urothelial cancer, pharynx cancer, head and neck cancer, rectal cancer, or any combination thereof.

### Claim 55 (depends on 52)

The method of claim 52, wherein the cancer is a hematological cancer, e.g., a hematological cancer chosen from a leukemia or lymphoma, e.g., the cancer is chosen from chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), multiple myeloma, acute lymphoid leukemia (ALL), Hodgkin lymphoma, B-cell acute lymphoid leukemia (BALL), T-cell acute lymphoid leukemia (TALL), small lymphocytic leukemia (SLL), B cell prolymphocytic leukemia, blastic plasmacytoid dendritic cell neoplasm, Burkitt's lymphoma, diffuse large B cell lymphoma (DLBCL), DLBCL associated with chronic inflammation, chronic myeloid leukemia, myeloproliferative neoplasms, follicular lymphoma, pediatric follicular lymphoma, hairy cell leukemia, small cell- or a large cell-follicular lymphoma, malignant lymphoproliferative conditions, MALT lymphoma (extranodal marginal zone lymphoma of mucosa-associated lymphoid tissue), Marginal zone lymphoma, myelodysplasia, myelodysplastic syndrome, non-Hodgkin lymphoma, plasmablastic lymphoma, plasmacytoid dendritic cell neoplasm, Waldenstrom macroglobulinemia, splenic marginal zone lymphoma, splenic lymphoma/leukemia, splenic diffuse red pulp small B-cell lymphoma, hairy cell leukemia-variant, lymphoplasmacytic lymphoma, a heavy chain disease, plasma cell myeloma, solitary plasmocytoma of bone, extraosseous plasmocytoma, nodal marginal zone lymphoma, pediatric nodal marginal zone lymphoma, primary cutaneous follicle center lymphoma, lymphomatoid granulomatosis, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma, ALK+ large B-cell lymphoma, large B-cell lymphoma arising in HHV8-associated multicentric Castleman disease, primary effusion lymphoma, B-cell lymphoma, acute myeloid leukemia (AML), or unclassifiable lymphoma.

### Claim 56 (depends on 50, 51, 52, 53, 54, 55)

The method of any of claims 50-55, wherein the cell is administered systemically or locally.

### Claim 57 (depends on 56)

The method of claim 56, wherein the subject has a tumor, e.g., a solid tumor, and the cell, is administered through intratumoral administration.

### Claim 58 (depends on 50, 51, 52, 53, 54, 55, 56, 57)

The method of any one of claims 50-57, further comprising administering a third therapeutic agent, e.g., as described herein.

### Claim 59 (depends on 58)

The method of claim 58, wherein the third therapeutic agent is a checkpoint modulator, optionally wherein the third therapeutic agent is an anti-PD-1 antibody molecule, an anti-PD-L1 antibody molecule, an anti-CTLA-4 antibody molecule, an anti-TIM-3 antibody molecule, or an anti-LAG-3 molecule.

### Claim 60

A method of evaluating or predicting a subject's responsiveness to a CAR-expressing cell therapy, comprising acquiring a value for the level, e.g., activity or expression level, of CD45RO and CCR7 in the population of cells, wherein:
a low level of CD45RO expression (e.g., CD45RO−) and a high level of CCR7 expression (e.g., CCR7+) is indicative or predictive of increased responsiveness of the subject to the CAR IL-15/IL-15R-expressing cell therapy; and
a high level of CD45RO expression (e.g., CD45RO+) and a low level of CCR7 expression (e.g., CCR7−) is indicative or predictive of decreased responsiveness of the subject to the CAR IL-15/IL-15R-expressing cell therapy,
thereby evaluating or predicting the subject's responsiveness to the CAR IL-15/IL-15R expressing cell therapy.